Obermatt
See Similar Stocks →

Flags

Financial distress

Inventiva

PAR:IVA · FR0013233012
BiotechnologySmall

360

16
Profit price16
Owner Earnings Yield1
Dividend Yield1
Price/Sales8
EV / Gross Profit1
Price/Book76
Return on Capital10
Cash Return on Capital4
Profit margins30
Accruals93
Owner Earnings Margin1
Sales growth51
Profit growth24
Reinvestment92
Price momentum57
Debt load15
Refinancing94
Debt Payback1
Liquidity54
Analyst ratings73
Opinion Changes50
Price Target Upside77
Market mood27
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Inventiva doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryFrance
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded2011
Employees101
Websiteinventivapharma.com
ISINFR0013233012
Last UpdateApr 2, 2026
Indices
CAC All (France)NASDAQ (USA)
Themes
InflammationPulmonologyGeneticsRheumatologyChronic DiseasesHepatologyDiabetesOncologyBiopharmaBiotechnologyClinical TrialsMedicalMedical Device

Description

Inventiva S.A. operates as a clinical-stage biopharmaceutical company. The company focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company operates a wholl…

Analysis

Hope premium

Inventiva S.A. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
68
2026

All-time high

82

Mar 2026

All-time low

68

Jun 2026

Average rank

75

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
8
—
—
—
Price/Earnings
43
—
—
—
Price/Book
76
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
31
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Inventiva with its peers
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Adocia
PAR:ADOC
63
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Heidelberg Pharma
GER:HPHA
32
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immatics
NAQ:IMTX
31
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tiziana Life Sciences
NAQ:TLSA
67
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Compugen
NAQ:CGEN
19
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →